AxoGen (AXGN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
23 Jun, 2026Opening remarks and agenda
Meeting opened virtually to enable broader shareholder participation.
Board members, management, and external representatives were introduced.
Meeting procedures, voting rights, and question submission process were outlined.
Board and executive committee updates
Eight directors were nominated for election to serve until the 2027 annual meeting.
Committee chairs for Audit, Compensation, Governance, and Quality were introduced.
Shareholder proposals
Three proposals were presented: election of directors, ratification of the independent auditor, and a non-binding advisory vote on executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AxoGen
- Rapidly growing nerve repair leader with FDA-approved products and expanding market access.AXGN
Corporate presentation - Q2 2026 revenue up 23.1% to $69.7M, led by Breast segment growth and raised full-year guidance.AXGN
Q2 2026 - Unified strategy, reimbursement gains, and clinical advances position for sustained growth.AXGN
Bank of America Global Healthcare Conference 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance focus.AXGN
Proxy filing - Q1 2026 revenue up 26.6% to $61.5M; guidance raised and liquidity strengthened after debt repayment.AXGN
Q1 2026 - Broad BLA label, exclusivity, and expanded coverage drive growth in nerve care markets.AXGN
The Citizens Life Sciences Conference 2026 - Strong revenue growth and FDA approval drive improved results and positive 2026 outlook.AXGN
Q4 2025 - Innovative biologics, new codes, and education drive double-digit growth in a $5.6B market.AXGN
44th Annual J.P. Morgan Healthcare Conference - Q2 2024 revenue up 25.6% to $47.9M, net loss narrowed, and guidance raised for the year.AXGN
Q2 2024